Chemomab Therapeutics (CMMB) Prepaid Assets (2019 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Prepaid Assets came in at $3.1 million in Q4 2025, up 80.15% YoY from $1.7 million in Q4 2024, and up 77.75% on a QoQ basis from $1.7 million in Q3 2025.
Chemomab Therapeutics (CMMB) Prepaid Assets (2019 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 7 years of Prepaid Assets data on file, last reported at $3.1 million in Q4 2025.
- Quarterly Prepaid Assets rose 80.15% year-over-year to $3.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.1 million (up 80.15% YoY) and the FY2025 annual result came in at $3.1 million, up 80.15% from the prior year.
- Prepaid Assets rose to $3.1 million in Q4 2025, from $1.7 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $3.1 million in Q2 2022 to a low of $320000.0 in Q1 2021.
- A 5-year average of $1.5 million and a median of $1.4 million in 2021 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2021 — Prepaid Assets soared 982.98% — and 2023, when it sank 66.45%.
- Tracing CMMB's Prepaid Assets over 5 years: stood at $1.5 million in 2021, then increased by 15.65% to $1.8 million in 2022, then tumbled by 41.28% to $1.0 million in 2023, then jumped by 63.74% to $1.7 million in 2024, then soared by 80.15% to $3.1 million in 2025.
- The last three Prepaid Assets figures came in at $3.1 million (Q4 2025), $1.7 million (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Chemomab Therapeutics | 13.62 Mn | 3.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.06 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Dec 31, 2024 | 1.70 Mn |
| Sep 30, 2024 | 439,000.00 |
| Jun 30, 2024 | 654,000.00 |
| Mar 31, 2024 | 885,000.00 |
| Dec 31, 2023 | 1.04 Mn |
| Sep 30, 2023 | 922,000.00 |
| Jun 30, 2023 | 1.04 Mn |
| Mar 31, 2023 | 995,000.00 |
| Dec 31, 2022 | 1.77 Mn |
| Sep 30, 2022 | 2.26 Mn |
| Jun 30, 2022 | 3.11 Mn |
| Mar 31, 2022 | 1.93 Mn |
| Dec 31, 2021 | 1.53 Mn |
| Sep 30, 2021 | 1.57 Mn |
| Jun 30, 2021 | 1.92 Mn |
| Mar 31, 2021 | 320,000.00 |